drugset
drugset / Trial / NCT03045328

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

NCT03045328 ↗

Phase 2 Completed 22 enrolled Steven E. Coutre
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label non-randomized two-center phase 2 study evaluating the safety and efficacy of concurrent therapy with ibrutinib and venetoclax in subjects with relapsed or refractory CLL/SLL.

Timeline

Start
2017-09-26
Primary completion
2020-05-19
Completion
2021-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 420 mg Oral
Subject Venetoclax Small molecule 20 mg Oral
Subject Venetoclax Small molecule 50 mg Oral
Subject Venetoclax Small molecule 100 mg Oral
Subject Venetoclax Small molecule 200 mg Oral
Subject Venetoclax Small molecule 400 mg Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma